ABEO
Abeona Therapeutics Inc.
Biotechnology
Market Cap$318M
5Y Perf.-93.0%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
ABEO vs RARE
Revenue, margins, valuation, and 5-year total return — side by side.
RARE
Ultragenyx Pharmaceutical Inc.
Biotechnology
Market Cap$2.57B
5Y Perf.-61.8%
ABEO vs RARE — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ABEO | RARE |
|---|---|---|
| Industry | Biotechnology | Biotechnology |
| Market Cap | $318M | $2.57B |
| Revenue (TTM) | $6M | $669M |
| Net Income (TTM) | $71M | $-609M |
| Gross Margin | 26.3% | 83.6% |
| Operating Margin | -15.4% | -83.9% |
| Forward P/E | 5.7x | — |
| Total Debt | $25M | $1.28B |
| Cash & Equiv. | $78M | $434M |
ABEO vs RARE — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
ABEO
RARE
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Abeona Therapeutics… (ABEO) | 100 | 7.0 | -93.0% |
| Ultragenyx Pharmace… (RARE) | 100 | 38.2 | -61.8% |
Price return only. Dividends and distributions are not included.
Quick Verdict: ABEO vs RARE
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: ABEO leads in 5 of 6 categories, making it the strongest pick for growth and revenue expansion and profitability and margin quality. As sector peers, any of these can serve as alternatives in the same allocation.
ABEO
Abeona Therapeutics Inc.
The Income Pick
ABEO carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.
- Dividend streak 1 yrs, beta 1.34
- EPS growth 165.2%, 3Y rev CAGR 60.3%
- Lower volatility, beta 1.34, Low D/E 15.7%, current ratio 6.93x
Best for: income & stability and growth exposure
RARE
Ultragenyx Pharmaceutical Inc.
The Long-Run Compounder
RARE is the clearest fit if your priority is long-term compounding.
- -59.4% 10Y total return vs ABEO's -90.7%
Best for: long-term compounding
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | ABEO | 222.9% revenue growth vs RARE's 20.1% |
| Quality / Margins | ABEO | 12.2% margin vs RARE's -91.0% |
| Stability / Safety | ABEO | Beta 1.34 vs RARE's 1.42 |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | ABEO | +9.5% vs RARE's -21.8% |
| Efficiency (ROA) | ABEO | 35.8% ROA vs RARE's -45.8%, ROIC -89.8% vs -89.4% |
ABEO vs RARE — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
FY 2025
FY 2025
ABEO vs RARE — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLABEOLAGGINGRARE
RAREUltragenyx Pharmaceut…
2leads
ABEOAbeona Therapeutics I…
2leads
6 Total Categories
CATEGORYLEADERvs RAREMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
RARE4/5
Valuation MetricsMultiples, price ratios, and targets
RARE2/2
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
ABEO6/8
Total Returns1Y, 3Y, 5Y total returns with dividends
Tied
—
Risk & VolatilityBeta, volatility, and downside exposure
ABEO2/2
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
RARE leads this category, winning 4 of 5 comparable metrics.
Income & Cash Flow (Last 12 Months)
RARE is the larger business by revenue, generating $669M annually — 115.0x ABEO's $6M. ABEO is the more profitable business, keeping 12.2% of every revenue dollar as net income compared to RARE's -91.0%.
| Metric | ABEOAbeona Therapeuti… | RAREUltragenyx Pharma… |
|---|---|---|
| RevenueTrailing 12 months | $6M | $669M |
| EBITDAEarnings before interest/tax | -$86M | -$536M |
| Net IncomeAfter-tax profit | $71M | -$609M |
| Free Cash FlowCash after capex | -$84M | -$487M |
| Gross MarginGross profit ÷ Revenue | +26.3% | +83.6% |
| Operating MarginEBIT ÷ Revenue | -15.4% | -83.9% |
| Net MarginNet income ÷ Revenue | +12.2% | -91.0% |
| FCF MarginFCF ÷ Revenue | -14.5% | -72.8% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | -2.4% |
| EPS Growth (YoY)Latest quarter vs prior year | -56.5% | -17.2% |
RARE leads this category, winning 4 of 5 comparable metrics.
Valuation Metrics
RARE leads this category, winning 2 of 2 comparable metrics.
Valuation Metrics
| Metric | ABEOAbeona Therapeuti… | RAREUltragenyx Pharma… |
|---|---|---|
| Market CapShares × price | $318M | $2.6B |
| Enterprise ValueMkt cap + debt − cash | $264M | $3.4B |
| Trailing P/EPrice ÷ TTM EPS | 5.71x | -4.48x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | 54.57x | 3.82x |
| Price / BookPrice ÷ Book value/share | 2.40x | — |
| Price / FCFMarket cap ÷ FCF | — | — |
RARE leads this category, winning 2 of 2 comparable metrics.
Profitability & Efficiency
ABEO leads this category, winning 6 of 8 comparable metrics.
Profitability & Efficiency
ABEO delivers a 53.2% return on equity — every $100 of shareholder capital generates $53 in annual profit, vs $-6 for RARE. On the Piotroski fundamental quality scale (0–9), ABEO scores 6/9 vs RARE's 4/9, reflecting solid financial health.
| Metric | ABEOAbeona Therapeuti… | RAREUltragenyx Pharma… |
|---|---|---|
| ROE (TTM)Return on equity | +53.2% | -6.1% |
| ROA (TTM)Return on assets | +35.8% | -45.8% |
| ROICReturn on invested capital | -89.8% | -89.4% |
| ROCEReturn on capital employed | -63.4% | -46.4% |
| Piotroski ScoreFundamental quality 0–9 | 6 | 4 |
| Debt / EquityFinancial leverage | 0.16x | — |
| Net DebtTotal debt minus cash | -$53M | $842M |
| Cash & Equiv.Liquid assets | $78M | $434M |
| Total DebtShort + long-term debt | $25M | $1.3B |
| Interest CoverageEBIT ÷ Interest expense | 19.23x | -14.49x |
ABEO leads this category, winning 6 of 8 comparable metrics.
Total Returns (Dividends Reinvested)
Evenly matched — ABEO and RARE each lead in 3 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in RARE five years ago would be worth $2,281 today (with dividends reinvested), compared to $1,499 for ABEO. Over the past 12 months, ABEO leads with a +9.5% total return vs RARE's -21.8%. The 3-year compound annual growth rate (CAGR) favors ABEO at 22.6% vs RARE's -17.8% — a key indicator of consistent wealth creation.
| Metric | ABEOAbeona Therapeuti… | RAREUltragenyx Pharma… |
|---|---|---|
| YTD ReturnYear-to-date | +8.7% | +10.7% |
| 1-Year ReturnPast 12 months | +9.5% | -21.8% |
| 3-Year ReturnCumulative with dividends | +84.3% | -44.5% |
| 5-Year ReturnCumulative with dividends | -85.0% | -77.2% |
| 10-Year ReturnCumulative with dividends | -90.7% | -59.4% |
| CAGR (3Y)Annualised 3-year return | +22.6% | -17.8% |
Evenly matched — ABEO and RARE each lead in 3 of 6 comparable metrics.
Risk & Volatility
ABEO leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
ABEO is the less volatile stock with a 1.34 beta — it tends to amplify market swings less than RARE's 1.42 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. ABEO currently trades 76.5% from its 52-week high vs RARE's 61.7% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ABEOAbeona Therapeuti… | RAREUltragenyx Pharma… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.34x | 1.42x |
| 52-Week HighHighest price in past year | $7.54 | $42.37 |
| 52-Week LowLowest price in past year | $4.00 | $18.29 |
| % of 52W HighCurrent price vs 52-week peak | +76.5% | +61.7% |
| RSI (14)Momentum oscillator 0–100 | 69.4 | 66.6 |
| Avg Volume (50D)Average daily shares traded | 1.2M | 1.8M |
ABEO leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates ABEO as "Buy" and RARE as "Buy". Consensus price targets imply 194.6% upside for ABEO (target: $17) vs 97.1% for RARE (target: $52).
| Metric | ABEOAbeona Therapeuti… | RAREUltragenyx Pharma… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $17.00 | $51.50 |
| # AnalystsCovering analysts | 9 | 33 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | 1 | 1 |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
RARE leads in 2 of 6 categories (Income & Cash Flow, Valuation Metrics). ABEO leads in 2 (Profitability & Efficiency, Risk & Volatility). 1 tied.
Best OverallAbeona Therapeutics Inc. (ABEO)Leads 2 of 6 categories
Loading custom metrics...
ABEO vs RARE: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is ABEO or RARE a better buy right now?
Abeona Therapeutics Inc.
(ABEO) offers the better valuation at 5. 7x trailing P/E, making it the more compelling value choice. Analysts rate Abeona Therapeutics Inc. (ABEO) a "Buy" — based on 9 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — ABEO or RARE?
Over the past 5 years, Ultragenyx Pharmaceutical Inc.
(RARE) delivered a total return of -77. 2%, compared to -85. 0% for Abeona Therapeutics Inc. (ABEO). Over 10 years, the gap is even starker: RARE returned -59. 4% versus ABEO's -90. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — ABEO or RARE?
By beta (market sensitivity over 5 years), Abeona Therapeutics Inc.
(ABEO) is the lower-risk stock at 1. 34β versus Ultragenyx Pharmaceutical Inc. 's 1. 42β — meaning RARE is approximately 6% more volatile than ABEO relative to the S&P 500.
04Which is growing faster — ABEO or RARE?
On earnings-per-share growth, the picture is similar: Abeona Therapeutics Inc.
grew EPS 165. 2% year-over-year, compared to 7. 3% for Ultragenyx Pharmaceutical Inc.. Over a 3-year CAGR, ABEO leads at 60. 3% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — ABEO or RARE?
Abeona Therapeutics Inc.
(ABEO) is the more profitable company, earning 1223% net margin versus -85. 4% for Ultragenyx Pharmaceutical Inc. — meaning it keeps 1223% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: RARE leads at -79. 5% versus -1536. 9% for ABEO. At the gross margin level — before operating expenses — RARE leads at 83. 8%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — ABEO or RARE?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is ABEO or RARE better for a retirement portfolio?
For long-horizon retirement investors, Abeona Therapeutics Inc.
(ABEO) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding. Both have compounded well over 10 years (ABEO: -90. 7%, RARE: -59. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between ABEO and RARE?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: ABEO is a small-cap deep-value stock; RARE is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.